Clinical trial
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and…
NCT00450385 · University of Miami, Other · Terminated
Key facts
| NCT number | NCT00450385 |
|---|---|
| Title | Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) |
| Official title | Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP |
| Acronym | R-CHOP |
| Lead sponsor | University of Miami, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Vincristine |
| Enrollment | 57 |
| Start date | Apr 24, 2007 |
| Primary completion | May 1, 2016 |
| Completion | May 1, 2016 |
| First posted | Mar 22, 2007 |
| Last update posted | Jun 23, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: